Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma

Geraldine Faivre, Matthew James Butler, Isabelle Le, Andrew Brenner

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Optimal management of elderly patients with primary central nervous system lymphoma (PCNSL) after induction therapy is unclear. In our retrospective series of 10 patients treated with temozolomide after induction with R-MPV (rituximab, methotrexate, procarbazine and vincristine) we found a median progression-free survival of 57 months, and a median overall survival of 63 months, with moderate toxicity, which supports the idea that temozolomide might have activity for maintenance in elderly patients with PCNSL.

Original languageEnglish (US)
Pages (from-to)665-669
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Volume19
Issue number10
DOIs
StatePublished - Oct 2019

Keywords

  • Consolidation
  • MTX
  • PCNSL
  • R-MPV
  • TMZ

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma'. Together they form a unique fingerprint.

Cite this